Abstract
Acne vulgaris, a multi-factorial disease, is one of the most common skin diseases, affecting an estimated 80% of Americans at some point during their lives. The gram-positive and anaerobic Propionibacterium acnes (P. acnes) bacterium has been implicated in acne inflammation and pathogenesis. Therapies for acne vulgaris using antibiotics generally lack bacterial specificity, promote the generation of antibiotic-resistant bacterial strains, and cause adverse effects. Immunotherapy against P. acnes or its antigens (sialidase and CAMP factor) has been demonstrated to be effective in mice, attenuating P. acnes-induced inflammation; thus, this method may be applied to develop a potential vaccine targeting P. acnes for acne vulgaris treatment. This review summarizes reports describing the role of P. acnes in the pathogenesis of acne and various immunotherapy-based approaches targeting P. acnes, suggesting the potential effectiveness of immunotherapy for acne vulgaris as well as P. acnes-associated diseases.
Keywords: Acne vulgaris, Immunotherapy, Propionibacterium acnes.
Current Drug Metabolism
Title:Propionibacterium acnes in the Pathogenesis and Immunotherapy of Acne Vulgaris
Volume: 16 Issue: 4
Author(s): Pei-Feng Liu, Yao-Dung Hsieh, Ya-Ching Lin, Aimee Two, Chih-Wen Shu and Chun-Ming Huang
Affiliation:
Keywords: Acne vulgaris, Immunotherapy, Propionibacterium acnes.
Abstract: Acne vulgaris, a multi-factorial disease, is one of the most common skin diseases, affecting an estimated 80% of Americans at some point during their lives. The gram-positive and anaerobic Propionibacterium acnes (P. acnes) bacterium has been implicated in acne inflammation and pathogenesis. Therapies for acne vulgaris using antibiotics generally lack bacterial specificity, promote the generation of antibiotic-resistant bacterial strains, and cause adverse effects. Immunotherapy against P. acnes or its antigens (sialidase and CAMP factor) has been demonstrated to be effective in mice, attenuating P. acnes-induced inflammation; thus, this method may be applied to develop a potential vaccine targeting P. acnes for acne vulgaris treatment. This review summarizes reports describing the role of P. acnes in the pathogenesis of acne and various immunotherapy-based approaches targeting P. acnes, suggesting the potential effectiveness of immunotherapy for acne vulgaris as well as P. acnes-associated diseases.
Export Options
About this article
Cite this article as:
Liu Pei-Feng, Hsieh Yao-Dung, Lin Ya-Ching, Two Aimee, Shu Chih-Wen and Huang Chun-Ming, Propionibacterium acnes in the Pathogenesis and Immunotherapy of Acne Vulgaris, Current Drug Metabolism 2015; 16 (4) . https://dx.doi.org/10.2174/1389200216666150812124801
DOI https://dx.doi.org/10.2174/1389200216666150812124801 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Oral Cavity, Biofilms and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Secondary Prevention of Ischemic Stroke
Current Drug Targets The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) Current Research on Opioid Receptor Function
Current Drug Targets Emergence of Methicillin-Resistant Staphylococcus aureus (MRSA) as a Public-Health Threat and Future Directions of Antibiotic Therapy for MRSA Infections
Anti-Infective Agents Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Phytochemicals as Inhibitors of Candida Biofilm
Current Pharmaceutical Design Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Short Term Statin Treatment Improves Survival and Differentially Regulates Macrophage-Mediated Responses to Staphylococcus aureus
Current Pharmaceutical Biotechnology New Developments in Antimicrobial Use in Sepsis
Current Pharmaceutical Design Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Antibiotic Use in Children - Off-Label Use
Current Drug Targets Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Daptomycin: A Review of Properties, Clinical Use, Drug Delivery and Resistance
Mini-Reviews in Medicinal Chemistry Chemistry and Pharmacology of Natural Catechins from <i>Camellia sinensis</i> as Anti-MRSA Agents
Current Topics in Medicinal Chemistry New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design